Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Greulich (Marburg, Germany). Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study. 1801

Member's Comments

No comment yet.

Related content which might interest you: Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol/fluticasone (SFC): the FLAME study Source: International Congress 2017 – Management of COPD Year: 2017 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β2-agonist/corticosteroid (SUMMIT) Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Management of high risk patients with COPD, identified by the DOSE index, in general practice Source: Annual Congress 2009 - COPD case-finding and management in primary care Year: 2009 Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Prevalence of co-morbidities in Greek COPD patients in relation to the stage of the disease (COMPACT study) Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care Year: 2017 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Identifying a ‘frequent exacerbator‘ phenotype in a cohort of COPD patients (EXACO study) Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease Year: 2012 Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Two versus three months rehabilitation with the same number of sessions in patients with moderate to severe COPD: analysis of the results Source: Eur Respir J 2004; 24: Suppl. 48, 244s Year: 2004 Pilot: identification of rehospitalization risk factors for patients with COPD Source: Annual Congress 2005 - Assessment and intervention from primary care centre to hospital Year: 2005 Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study) Source: Eur Respir J , 49 (3) 1501885; DOI: 10.1183/13993003.01885-2015 Year: 2017